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Infection with Epstein-Barr virus (EBV) results in lifelong in-
fection of B cells in the peripheral blood and in episodic shedding of virus from the oropharynx. We monitored patients treated with rituximab (anti-CD20 monoclonal antibody) and found that several had both no detectable B cells and no EBV in the blood but shed EBV from the throat. Although some models postulate that EBV traffics from the B cells in the blood to the throat, where it is subsequently shed, our findings indicate that circulating EBV in B cells is not necessary for the virus to persist in, and to be shed from, the oropharynx.
Epstein-Barr virus (EBV) establishes latency after primary infection and can be detected in throat-wash or saliva samples from at least half of healthy seropositive adults [1] and from a greater proportion of immunosuppressed persons [2] . In latently infected persons, EBV is found in memory B cells in the blood [3] ; the virus reactivates in the oropharynx, releasing virus into the saliva.
The role that oropharyngeal epithelial cells play in the EBV life cycle is controversial. In situ hybridization has demonstrated EBV in epithelial cells from patients with infectious mononucleosis [4] . However, later studies of throat-wash and tonsil samples from patients with infectious mononucleosis and from healthy persons showed that EBV was present in B cells exclusively [5] . Patients with X-linked agammaglobulinemia lack mature B cells and have no evidence of EBV infection; therefore, mature B cells are essential for acquisition and/or maintenance of EBV [6] . However, latent EBV infection has been found in tonsillar epithelial cells cultured from asymptomatic donors [7] . Asymptomatic EBV carriers have EBV strains in the blood that often differ from those in the oropharynx [8] . These findings suggest that B cells are necessary but not sufficient for acquisition and maintenance of EBV infection and that infection also occurs in epithelial cells.
Studies of EBV in seropositive patients receiving bonemarrow transplants showed that some patients became seronegative after transplantation and that they subsequently acquired EBV either from their donor or a close contact [9] . Most of these patients received cyclophosphamide and total-body irradiation. These findings imply that EBV resides in the hematopoietic cells that are ablated by the bone marrow-transplantation process, via either cytotoxic chemotherapy, irradiation, or graft-versushost reactivity. Epithelial cells were presumed to remain after chemotherapy, and any EBV still in these cells was insufficient to continue the latent infection.
In the present study, we investigated whether selective depletion of circulating B cells results in loss or reduction of EBV shedding from the oropharynx. Rituximab (RTX), a monoclonal antibody against CD20, causes rapid and profound depletion of B cells from the blood; its half-life varies from days to weeks, and it can be detected in the serum months after administration [10] . In human studies using standard (375 mg/m 2 ) or higher single doses of RTX, the numbers of B cells are markedly reduced but are still detected in lymph nodes [11, 12] . In the present study, we measured the level of EBV in throat-wash and blood samples from patients receiving RTX.
Patients, materials, and methods. Patients at the National Institutes of Health (NIH) Clinical Center who were receiving RTX (10 mg/kg) for treatment of either lymphoma or cryoglobulinemia were enrolled in the study. Informed consent was obtained from the patients, and the study was approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases.
Throat-wash samples were collected by having the patient gargle for 10 s with 2 separate 10-mL aliquots of preservativefree normal saline; the combined 20-mL sample was centrifuged at low speed, and the pellets and supernatants were stored separately at Ϫ70°C. Heparinized blood samples were collected, and peripheral-blood mononuclear cells (PBMCs) were separated by Ficoll-Hypaque gradient centrifugation and were stored at Ϫ70°C.
DNA was extracted from throat-wash pellets by use of the Easy DNA Kit (Invitrogen). Quantitative real-time polymerase chain reaction (PCR) amplification was performed with 100 ng of each DNA sample, by use of a TaqMan PCR kit and a Model 7700 Sequence Detector (Applied Biosystems). Primers were obtained from Invitrogen, and fluorescent probes were obtained from Synthegen. Primers EBVW-F1 (5'-GGACCACTGCCCCTGGTATAA-3') and EBVW-R2 (5'-TTTGTGTGGACTCCTGGGG-3') were used to amplify the BamHI W region of the EBV genome, and the product was detected by use of fluorogenic probe EBVW (5' [6FAM]-TCCTGCAGCTATTTCTGGTCGCATCA-[TAMRA] 3'). Primers Bcl2-F (5'-CCTGCCCTCCTTCCGC-3') and Bcl2-R (5'-TGCATTTCAGGAAGACCCTGA-3') were used to amplify the human diploid Bcl2 gene, which was used as a control, and the PCR product was detected by use of a Bcl2 probe (5' [6FAM]-CTTTCTCATGGCTGTCC-[TAMRA] 3'). Each experiment included standard curves based on dilutions of plasmid DNA containing the EBV BamHI W or Bcl2 sequences. The number of EBV BamHI W copies per cell (N) was calculated as N ϭ (2 ϫ W)/B, where W is the EBV BamHI W copy number and B is the Bcl2 copy number. The limit of detection of the reaction was 5 copies per well. Values for EBV DNA in throatwash samples were expressed as the number of copies per 10 6 cells. EBV detection in blood samples was performed by the Department of Laboratory Medicine of the NIH Clinical Center, as described elsewhere [13] . Values were expressed as the number of EBV genome copies per 10 6 PBMCs, with the lower limit of detection varying when patients had very low total PBMC counts.
The stored aliquots of PBMCs were thawed, washed, incubated with antibodies to CD19 or CD20 (BD Biosciences), and analyzed by flow cytometry using FACSCalibur (BD Biosciences).
Results. In the first study, we determined whether EBV DNA could be detected in throat-wash samples from patients who had recently received RTX; we recruited patients already receiving RTX as part of their therapy for lymphoma. Most treatment protocols included administration of RTX at 3-week intervals, along with cycles of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH-R). Because of the rapid effect and long half-life of RTX, we reasoned that samples could be obtained at any point during the treatment cycle. We obtained 1-3 throat-wash and blood samples from each of 5 patients, with the timing being determined by what was convenient for the patient. Samples were obtained after patients had received 1-5 cycles of RTX therapy. We used real-time PCR to detect EBV DNA in cell pellets obtained by centrifugation of throat-wash samples, because cell pellets have a greater sensitivity for detection of EBV than do throat-wash supernatants [2] . Of the 5 patients, 3 had detectable EBV DNA in their throatwash samples 1-21 days after having received the last doses of RTX (table 1) ; of the 2 patients who did not have detectable EBV NOTE. DLBCL, diffuse large-B-cell lymphoma; EPOCH-R, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and RTX. a A value preceded by a "less than" sign (i.e., Ͻ) indicates that the amount was below the limit of detection. The limit of detection varied with the patient's total white-blood-cell count on that day. NOTE. BϩEPOCH-R, treatment with bortezomib followed by treatment with EPOCH-R; DLBCL, diffuse large-B-cell lymphoma; EPOCH-R, treatment with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and RTX. a A value preceded by a "less than" sign (i.e., Ͻ) indicates that the amount was below the limit of detection. The limit of detection varied with the patient's total white-blood-cell count on that day.
DNA in throat-wash samples, 1 (patient 3) was known to be EBV seropositive, and the other (patient 1) was not tested for EBV antibodies. No patient had detectable EBV DNA in PBMCs while receiving RTX. Five samples from 2 patients receiving RTX had Ͻ0.3% CD19 ϩ B cells, indicating that RTX had effectively depleted B cells (data not shown).
Having detected EBV DNA in throat-wash samples from patients receiving RTX, we determined whether the amount of shedding changed in response to therapy. In a second study, which included 12 patients who had not yet started RTX therapy, we collected blood and throat-wash samples on at least 1 occasion before therapy, at least once during each cycle of therapy, and 3 months after the last cycle of therapy.
Before the start of therapy, the level of EBV DNA in the oropharynx varied among patients, as has been observed elsewhere [1, 2] . Seven patients (patients 6 -9, 11, 14, and 15) who shed EBV before therapy continued to shed EBV episodically at high levels (Ͼ1000 EBV DNA copies/10 6 throat-wash cells) during RTX therapy (table 2) . One patient (patient 11) maintained high levels of shedding at follow-up visits up to 8 weeks after having received the last dose of RTX. One patient who shed EBV before therapy (patient 12) shed low levels of EBV (Ͻ200 EBV copies/ 10 6 throat-wash cells) after therapy. Two patients (patients 10 and 13) who had no detectable shedding before therapy shed low levels of EBV (300 EBV copies/10 6 throat-wash cells) after receiving RTX. One patient (patient 17) shed no detectable EBV throughout the study but was found to be seropositive for EBV. All of these patients were receiving cytotoxic chemotherapy in addition to RTX, and the chemotherapy might have affected EBV shedding. Because cytotoxic chemotherapy might either reduce shedding (by killing epithelial cells) or enhance shedding (by either reducing immunosurveillance by cytotoxic T cells or reactivating EBV DNA from latently infected B cells), we studied a patient (patient 16) who was receiving RTX but not cytotoxic chemotherapy. This patient was receiving RTX for cryoglobulinemia and was also found to shed EBV from the oropharynx during therapy.
CD20 ϩ B cells were measured in the peripheral blood of 10 patients before and during RTX therapy. In most patients, RTX rapidly reduced and virtually eliminated circulating CD20 ϩ B cells after the first dose and eliminated detectable EBV DNA in PBMCs (table 2) . Four patients (patients 6, 7, 9, and 14) continued to shed high levels of EBV (Ͼ1000 EBV DNA copies/10 6 throat-wash cells) from the throat and had no detectable EBV DNA in their PBMCs and no or very few (Ͻ0.3%) circulating CD20 ϩ B cells during RTX therapy (table 2) . Three patients (patients 10, 12, and 13) who shed low levels of EBV (Ͻ300 EBV copies/10 6 throat-wash cells) from the throat after RTX therapy had no detectable EBV DNA in PBMCs and low levels (0.2%) of circulating CD20 ϩ B cells during that therapy. One patient (patient 8) shed high levels of EBV from the throat and had no detectable EBV in PBMCs but had somewhat higher levels (0.74%) of CD20 ϩ B cells in the blood while receiving RTX.
Two patients (patients 11 and 15) with mantle-cell lymphoma continued to have substantial numbers of CD20 ϩ B cells in their peripheral blood despite receiving RTX. To determine whether EBV DNA in throat-wash samples was in virions or was released as free viral DNA from infected cells, supernatant fractions corresponding to cell pellets either were used for PCR directly or were treated with DNAse to digest free DNA, heated to inactivate DNAse, and then subjected to PCR. Only 1 sample had detectable EBV DNA, of which only 20% was resistant to DNAse and therefore was encapsidated in virions indicative of virus replication (data not shown). Discussion. In the present study, we have shown that patients receiving RTX shed EBV DNA from the oropharynx at times when they have no or very few detectable circulating CD20 ϩ B cells. In contrast to the results of previous studies of myeloablative therapy followed by bone-marrow transplantation, the present study found no cases in which EBV shedding was completely eradicated by RTX. The results of the present study suggest that EBV persists in a cell population that is not depleted by RTX, such as oropharyngeal epithelial cells or B cells within lymphoid tissue, in which it can survive until circulating B cells return.
Detection of similar EBV strains in peripheral-blood lymphocytes and in oral hairy-leukoplakia lesions from the same patient suggests that EBV may be spread from the blood to the oropharynx [14] . At least 3 pathways have been proposed as accounting for the transit of EBV from cells circulating in the blood to epithelial cells, where productive infection occurs [14, 15] . First, EBV could traffic from B cells in the blood to the oropharynx, where the virus reactivates and infects epithelial cells. Second, EBV in pre-Langerhans cells circulating in the blood might traffic to the oropharynx, where they mature into EBV-infected Langerhans cells and infect epithelial cells [14] . Third, EBV in circulating B cells may infect circulating monocytes, which might subsequently infect epithelial cells [15] .
In addition to circulating EBV-infected cells trafficking to the oropharynx, EBV might persist in B cells in lymphoid tissues in the throat. Because RTX does not entirely deplete B cells from lymph nodes [11, 12] , persistence of EBV-infected B cells in lymphoid tissue may allow the virus to persist during RTX therapy. EBV is present at similar levels in memory B cells in the peripheral blood and in the adenoids and tonsils of Waldeyer's ring [3] ; therefore mucosal lymphoid tissues in the oropharynx could be a site of persistent infection during RTX therapy. Although, at present, we cannot determine whether EBV persistence in the oropharynx is a result of trafficking to the site by non-B cells and/or persistence of EBV-infected B cells in oropharyngeal lymphoid tissues, the results of the present study indicate that circulating EBV-infected B cells are not required for persistent shedding of EBV from the oropharynx.
